The Genomic Medicine Research Group is focused on using genetic knowledge and cutting-edge technologies to improve our understanding of human disease, with a view to enhancing diagnosis and treatment of complex disorders. Our team of researchers are particularly interested in the role of epigenetics, the function of microRNAs and investigation of genetic mutations which contribute to development of disease. Using a variety of in vitro, in vivo and in silico approaches, a number of overlapping projects in our group are carrying out ground-breaking research into various disease areas, including cancer, eye disease, cardiovascular disease and mental health.
Our work utilises state-of-the-art equipment available in the Genomics Core Facility Unit, including instrumentation for flow cytometry, imaging, PCR, sequencing and methylation analysis. We use several unique in vitro and in vivo disease models for our research, and techniques routinely employed in our research include CRISPR/Cas gene editing, gene silencing, DNA methylation analysis and reporter assays. Our cell biology laboratory work is complemented by bioinformatics expertise within the group to perform genome-wide association studies and other analyses of publicly available datasets.
Together, the group members have several strategic national and international research collaborations across academia, healthcare and industry, with an exciting track record of research outputs and conference presentations across the globe. Genomic research is absolutely crucial in the drive towards personalized medicine and tailored treatment for disease and the Genomic Medicine Research Group at Ulster are proud to be making a valuable contribution to this effort. Through our work we aim to facilitate translational medical research from laboratory to clinic, thereby helping to fulfil the great promise of genomic medicine.
Biomedical Science at Ulster University has an outstanding and sustained record of success in research, recognised in the most recent REF2021 to be internationally excellent, world leading and ranked 5th out of 89 UK universities within the category of Allied Health Professions which encompasses the disciplines of biomedical sciences, nursing, nutrition, pharmacy, optometry, health sciences and personalised medicine. Our research is not only producing outputs of world leading quality but also credited with having significant global translation, impacting positively on health professionals, industry, the general public and specific patient groups. We are proud to have externally recognised world-leading research environment which scored 100% 4*rating in REF 2014 and 2021.
Biomedical Sciences research activities are currently organised within distinct Research Centres: Diabetes, Food & Health (through Nutrition Innovation Centre for Food and Health (NICHE)), Genomic Medicine, Pharmaceutical Sciences & Practice, Personalised Medicine and Optometry & Vision Science.
Multi-disciplinary collaboration between the research groups is strongly encouraged and is widespread with research into, for instance, anti-diabetic and antioncogenic aspects of nutrition, the genomics of vitamin receptors, visual deterioration or cancer, imaging of neovascularisation. Our research investigates the interaction between cardiovascular disease and vision and the impact of health and disease, diet, diabetes on dementia, hypertension, autoimmunity, vascular and inflammatory disease, to name a few.
The research groups collaborate both internally and internationally on a range of prioritized multi-disciplinary themes in functional foods, gene-nutrient interactions; pregnancy and early life; healthy ageing, musculoskeletal health; drug discovery and delivery, personalized medicine and genomic medicine. The BMSRI has strong collaborations with regional and global pharmaceutical and diagnostics companies and many of our graduates and postgraduates gain employment in the government bodies, pharma, diagnostics, and health care sectors as well as academia and through self-employment.
The Biomedical Sciences Research Institute (BMSRI) offers a “state-of-the-art” research environment for high profile researchers to undertake internationally agenda setting research in strategically prioritized areas of biomedicine. This research environment within Biomedical Sciences at Ulster has been continually judged as exceptional and world-leading and awarded the highest 100% ranking within the RAE2008, REF2014 and REF2021. Furthermore, in the Postgraduate Research Experience Survey (PRES) awards, it was ranked 2nd in the UK, with an overall satisfaction rate of 88%.
Our research is carried out in well-equipped laboratories allowing the latest methods to be applied to individual projects. Our infrastructure is managed as Core Facility Units (CFUs) with equipment and laboratories dedicated to supporting pre-clinical studies, controlled human trials with expertise in vascular research, advanced molecular bioimaging/microscopy, bioinformatics, cell technologies, cellular biology, chemical analysis, genomics, proteomics/metabolomics (including mass spectrometry & NMR analysis), ocular imaging and psychophysics, transgenics, physiology and pharmacology.
The BMSRI research infrastructure also includes centralized resources for: high throughput drug screening in vitro assays, clinical research & human intervention studies/ trials; the use and storage of mammalian cells and tissues; and in vivo studies and animal models that replicate human disease. The BMSRI uses its estate of equipment, specialist laboratories, infrastructure and internationally recognized biomedical expertise to offer clinical & translational services to Academic Researchers and Industrial Business partners. The BMSRI routinely engages in collaborative research with some of the world’s leading pharmaceutical and biomedical companies and through the support of Ulster’s Office of Innovation, the University has established a track record of success in the commercialization of its research outcomes.
Research within BMSRI frequently involves collaboration between clinicians, academics and businesses in the life and health sector contributing to the development and launch of innovative health technologies, medical devices, and therapeutics. In addition to high-spec capabilities such as human genome sequencing, flow-cytometry and tissue culture, the close proximity of our research centres to hospitals permits direct access to NHS diagnostic laboratories, Clinical staff, and expertise in research governance and healthcare economics.
The expansion of biomedical research during the last 10 years and more has led to the construction of the £14.5M Centre for Molecular Biosciences (CMB) at the Coleraine campus. This expansion in research infrastructure later led to the creation of a number of “virtual” centres of excellence which are housed within the CMB building, i.e., the Centre for Functional Genomics (CFG), the FEI Centre for Advanced Bioimaging (CFAI) and the Centre for Nutrition & Bone Health whose overall aim is to develop a new “all-Ireland” expert research capability focused on nutrition and bone health, particularly targeted at identifying strategies to prevent osteoporosis.
Applicants should hold, or expect to obtain, a First or Upper Second Class Honours Degree in a subject relevant to the proposed area of study. We may also consider applications from those who hold equivalent qualifications, for example, a Lower Second Class Honours Degree plus a Master’s Degree with Distinction.
In exceptional circumstances, the University may consider a portfolio of evidence from applicants who have appropriate professional experience which is equivalent to the learning outcomes of an Honours degree in lieu of academic qualifications.